OCT 24, 2019 09:43 PM PDT

Patients can Self-Inject Easily Using an Integrated Pre-Filled Syringe and Autoinjector

WRITTEN BY: Nupur Srivastava

The patients suffering from chronic disease require a regular dose of medicines, either orally or as injections. The patients prefer the self-injection method as it is easy to use, cost-effective, and prevents a monthly visit to the specialists.

Because chronic diseases require repeated dosing of medicines, the market for self-injections grew at over 22% per year towards nearly $80 billion by 2022.

“This move towards injection of biologics at home is a clear trend in our society and our industry, and it presents a clear challenge for device developers,” says John A. Merhige, Chief Commercial Officer, Credence MedSystems, Inc.

Video courtesy: Dove Medical Press 

Becton, Dickinson, and Company (BD) is a global leader in medical technology and self-injection systems. BD announced the launch of Intevia at Parental Drug Association’s (PDA) 2019 Universe of Pre-Filled Syringes and Injection Devices conference held in Gothenburg, Sweden. BD Intevia is a 1mL two-step integrated platform device that combines both an autoinjector and a pre-fillable syringe in one system (Image 1 and a Video). The system favorably optimizes patient self-injections with high-viscous drugs and therapies. 

Peter Nolan, Worldwide President, BD Medical - Pharmaceutical Systems, said: “BD Intevia is a new generation of BD autoinjectors that will help drug manufacturers seamlessly enhance drug delivery experience.” “For the patient, the platform technology is designed to promote patient ease of use when self-injecting, and it is supported by BD’s worldwide clinical injection expertise harnessing the latest research in drug delivery technology,” he added.

Image 1: The features of BD Intevia

The latest validation study participants highly rated BD Intevia autoinjector-prefill syringe and switching to the integrated disposable system for key product attributes as:

  • Overall acceptance, and
  • Confidence to control the start of injection.

Source: MarketSearchEngine, BD Intevia

About the Author
You May Also Like
DEC 10, 2019
Health & Medicine
DEC 10, 2019
Novel Gene Therapy Approved by FDA to Treat Spinal Muscular Atrophy in Pediatric Patients
The most common form of spinal muscular atrophy (SMA), a rare genetic disease, is caused by mutations of chromosome 5 in the gene, SMN1. SMN1 encodes...
DEC 10, 2019
Health & Medicine
DEC 10, 2019
Use of Functional Inhibitors of Acid Sphingomyelinase (FIASMA) to Treat Intracelluar Bacterial Infections
Researchers at Virginia Commonwealth University presented the findings of their study published in Life Science Alliance that certain a...
DEC 10, 2019
Health & Medicine
DEC 10, 2019
In Vivo Tissue Stem Cell and Progenitor Cell Genome Modification
A stem cell, by definition, must be able to self-replicate to make more stem cells and to differentiate into a mature cell type. They can be unipotent...
DEC 10, 2019
Health & Medicine
DEC 10, 2019
New drug to treat opioid use disorder during pregnancy is favorable for mom, and baby
On average, a baby is born in withdrawal from opioids every 15 minutes in the U.S., according to recent research. Opioid use during pregnancy can result in...
DEC 10, 2019
Clinical & Molecular DX
DEC 10, 2019
The Three Common Herbs Combating High Blood Pressure: Molecular Mechanism Revealed
Hypertension is also known as high blood pressure is a serious condition. According to the Centers for Disease Control and Prevention, about 1 of...
DEC 10, 2019
Clinical & Molecular DX
DEC 10, 2019
AcroMetrix BCR-ABL External Molecular Panel: An Accurate Testing Method for Chronic Myeloid Leukemia
To support the validation and verification of new assays in oncology testing, Thermo Fisher Scientific with AcroMetrix control products provides innov...
Loading Comments...